BaseSpace
Correlation
Engine-Public
Sign In
Register
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
rs3825942
,
SNCA
,
T cell differentiation
,
Allergy to pollen
,
Retina
,
Lipitor
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
claudin
(biogroup)
Summary
General Info
Body Atlas
Most Correlated Tissues
Pancreas
Sigmoid colon
Rectum colon
Spleen
Placenta
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
11p partial monosomy syndrome
Vesicular stomatitis Indiana virus disease
Sendai virus infection
Eczema
Contact dermatitis
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
CGP 60474
dinaciclib
OTS-167
GSK-1059615
Ions
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
MIR20B
491333
SLX1B
PPP2R2C
Sly
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
Testis and spermatid gene expression in mice with targeted knockdown of the multicopy gene Sly
Knockdown of SLX1 and SLY in developing spermatids
L1000 CMAP - Neural progenitor NPC.CAS9 cells treated with small molecule perturbagens
Renal gene expression profiles of epithelial and non-epithelial embryonic and adult tissue
L1000 CMAP - Non-small cell lung cancer A549.311 cells with CRISPR targeted gene knockouts
Explore Curated Studies Results
Literature
Most Relevant Literature
There were no matches for claudin
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)
Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor
Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Ca…
Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advan…
A Study to Assess the Antitumor Activity, Safety, Pharmacokinetics and Biomarkers of Zolbetuximab (I…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ